Safe Way to Cost Minimization
An agreement on technological transfer of full cycle production and distribution of biosimilars of rituximab, bevacizumab and trastuzumab has been signed between Russian Biotechnology Company BIOCAD and Karaganda pharmaceutical complex (Kazakhstan).
The agreement was signed on October 4 within the framework of XIII Forum of Interregional Cooperation between Kazakhstan and Russia held in Astana. The republican pharmaceutical complex was equipped with modern equipment, production processes were standardized, and personnel was trained. Thus cooperation between countries has been initiated, meaning that people in Kazakhstan will have access to essential drugs, while public costs of the Kazakhstan government will be minimized.
It is of note, that BIOCAD is the first manufacturer of biosimilars, transferring its technologies to colleagues from Kazakhstan, including all preclinical and clinical data for the above drugs. Production localization in the Republic will reduce the costs and save spending on purchase of drugs for cancer.